KLK6 Antibody, Biotin conjugated

說(shuō)明書

中文名稱：

KLK6兔多克隆抗體, Biotin偶聯(lián)
貨號(hào)：

CSB-PA842165LD01HU
規(guī)格：

￥880
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) KLK6 Polyclonal antibody
Uniprot No.：

Q92876
基因名：

KLK6
別名：

Bssp antibody; hK 6 antibody; hK6 antibody; Kallikrein 6 precursor antibody; Kallikrein related peptidase 6 antibody; Kallikrein-6 antibody; Kallikrein6 antibody; KLK 6 antibody; Klk 7 antibody; KLK 9 antibody; Klk29 antibody; Klk6 antibody; KLK6_HUMAN antibody; Klk7 antibody; KLK9 antibody; MGC9355 antibody; mGK 1 antibody; mGK1 antibody; MSP antibody; Neurosin antibody; Protease M antibody; Protease serine 18 antibody; Protease serine 9 antibody; PRSS 18 antibody; PRSS 9 antibody; PRSS18 antibody; PRSS9 antibody; Serine protease 18 antibody; Serine protease 9 antibody; SP 59 antibody; SP59 antibody; Tissue kallikrein antibody; TK antibody; Zyme antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Kallikrein-6 protein (22-244AA)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Biotin
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA
Protocols：

ELISA Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis.
基因功能參考文獻(xiàn)：
1. High KLK6 expression is associated with metastasis of colon cancer. PMID: 30015976
2. Results showed a significant downregulation of KLK6 mRNA expression in breast cancer (BC) tissue sections compared to the non-cancerous component. The expression of KLK6 is positively associated with tumor grade and is overexpressed in aggressive phenotypes such as TNBC. PMID: 29435805
3. KLK6-PAR2 expression is down-regulated and PAR1 is up-regulated when DeltaNp63beta expression is decreased, leading to EMT with enhancing migration and invasion through ERK signal reduction at the invasive front PMID: 29224812
4. KLK6 may be the key protease involved in the proteolytic modification of PFK-M. PMID: 29563071
5. Our data demonstrate for the first time increased levels of KLK6 in mucosal melanomas of the head and neck PMID: 27844409
6. Induction of autophagic processes through KLK6 expression may increase acquisition of resistance of gastric cancer cells to auranofin-induced autophagy. PMID: 27863404
7. Our data provide experimental evidence that KLK6 controls metastasis formation in colon cancer via specific downstream network of miRNA-mRNA effectors. PMID: 28431272
8. Data show that kallikrein 6 (KLK6) expression is induced in mouse and human skin during chronic glucocorticoid treatment. PMID: 27283773
9. FST and KLK6 may have significance in breast cancer detection PMID: 27168011
10. KLK6 overexpression and likely its proteolytic activity is associated with alterations in downstream miRNAs and their targets, and these differ with the molecular subtypes of breast cancer. PMID: 27093921
11. Molecular models of peptides were built into the KLK6 structure and the marked preference of the cut between the two R of the examined peptides was related to the extended conformation of the substrates PMID: 28254587
12. Our fine-mapping study has identified novel loci in the KLK6 region strongly associated with aggressive PCa. PMID: 28376164
13. mRNA expression levels of KLK6 and KLK8 in advanced serous ovarian cancer PMID: 27483364
14. Data indicate that elevated expression of microRNA-375 in head and neck squamous cell carcinoma (HNSCC) cells significantly reduces kallikrein 6 (KLK6), kallikrein 10 (KLK10), and matrix metalloproteinase 9 (MMP9) messenger RNA expression. PMID: 26172508
15. KLK6 expression was detected in head and neck tumor cell lines (FaDu, Cal27 and SCC25), but not in HeLa cervix carcinoma cells. PMID: 25990935
16. The results of this study indicated that reductions in kallikrein-6 and calpain-1 may contribute to the accumulation of alpha-synuclein in DLB. PMID: 25476568
17. KLK6 and KLK10 may be useful markers and potential therapeutic targets in gastroesophageal junction tumors PMID: 25649006
18. This study assessed the prognostic utility of human tissue kallikrein-like peptidases 6 and 10 (KLK6 and KLK10) and correlated their expression with histopathological and clinical parameters in gastric cancer. PMID: 25153389
19. KLK6 may represent a potential unfavorable prognostic biomarker for colon cancer. PMID: 25153391
20. KLK6 promotes the proliferation of lung tumoral cells and restrains their apoptosis in vitro via ligand-dependent EGFR and was dependent on the protease-activated receptor 2. PMID: 24643912
21. The level of KLK6 is significantly increased in the plasma samples from laryngeal cancer patients compared to the controls. PMID: 24669031
22. Our data suggest that de novo KLK6 expression during early liver carcinogenesis may induce production of Ubi(1-74) by post-translational modification of ubiquitin PMID: 24979321
23. KLK6 mRNA expression could be considered as an independent, unfavorable molecular prognostic biomarker in colorectal adenocarcinoma, with additional prognostic value in patients without regional or distant metastases PMID: 24430362
24. Data indicate there was no SNP in KLK6 was associated with altered risk of prostate cancer. PMID: 21741862
25. Neuropathological analysis following delivery of LV-Neurosin to alpha-syn tg mice resulted in reduced accumulation of alpha-syn and reversal of neurodegenerative alterations in wild type but not A53T alpha-syn tg mice PMID: 22508489
26. Patients with synucleinopathy displayed lower cerebrospinal fluid levels of neurosin and alpha-synuclein compared to controls and Alzheimer's disease patients. PMID: 23308173
27. KLK6 DNA methylation was significantly associated with pathological stage in prostate cancer patients operated by radical prostatectomy. PMID: 22874102
28. Decreased serum concentrations of KLK6 are found in patients with aneurysmal subarachnoid hemorrhage, with the lowest levels in patients who died PMID: 23049835
29. hsa-let-7 family member hsa-let-7a is a modulator of KLK6 protein expression that is independent of the KLK6 copy number status PMID: 23136250
30. KLK6 gene expression may have clinical utility as a marker of unfavorable prognosis for intracranial tumors, and consequently, it could be used as target for therapeutic intervention. PMID: 22477710
31. in colorectal cancer patients, lymph node KLK6 positivity indicated presence of aggressive tumour cells associated with poor prognosis and high risk of tumour recurrence PMID: 22699826
32. KLK6 is positioned to serve as a molecular trigger of select physiological processes involved in the development of astrogliosis PMID: 22505518
33. KLK6 expressed by stromal cells may considerably contribute to the aggressiveness of ovarian cancer PMID: 22505521
34. KLK6 is significantly upregulated and secreted in gastric cancer tissues and sera, suggesting that KLK6 might be used as a potential biomarker and therapeutic target for gastric cancer. PMID: 22373580
35. KLK6 immunostaining is an independent prognostic marker in patients with colorectal carcinoma. PMID: 22285222
36. High KLK6 is associated with ovarian cancer. PMID: 22102857
37. KLK6-induced intracellular Ca(2+) flux and tumor cell invasion critically depends on the protease-activated receptor 1 (PAR1). PMID: 21753781
38. KLK6 has a role in tumour proliferation and progression of NSCLC PMID: 19426157
39. upregulated in late stage epithelial ovarian cancer PMID: 20680316
40. KLK6 was up-regulated significantly in tissues and sera from patients with colon cancer and was associated closely with a poor prognosis. PMID: 21656738
41. KLK6 promotes lymphocyte survival by a mechanism that depends in part on activation of PAR1. PMID: 21464892
42. The expression of kallikrein 7 and kallikrein 6 in melanomas may be responsible for the loss of cell-cell adhesion. PMID: 21193224
43. an altered KLK6 expression may contribute to vascular abnormalities in Alzheimer's disease and vascular dementia PMID: 20846516
44. Neurosin targets extracellular alpha-synuclein in cultured cells. PMID: 20403393
45. Patients diagnosed with advanced multiple sclerosis showed mean CSF levels of kallikrein-related peptidase 6 (29 ng/ml) that were significantly higher than in neurological controls (25.5 ng/ml). PMID: 20836755
46. The expression of hK6 in ovarian cancer was higher than that in benign and borderline ovarian neoplasms. Expression is higher in the ovarian cancer of late stage, higher-grade, with lymph node metastasis and is associated with a poorer prognosis. PMID: 19950700
47. KLK6 expression in cancerous tissues may play an important role in the invasion and metastasis of primary breast carcinoma. PMID: 18992199
48. Data show that it was unable to distinguish men with and without prostate cancer using multiple kallikreins as urinary biomarkers. PMID: 19560453
49. characterization of human kallikrein 6 as a degradative protease with structural features more similar to trypsin than the regulatory kallikreins PMID: 11983703
50. X-ray crystallographic structure of KLK6. PMID: 12016211
顯示更多

收起更多
亞細(xì)胞定位：

Secreted. Nucleus, nucleolus. Cytoplasm. Mitochondrion. Microsome. Note=In brain, detected in the nucleus of glial cells and in the nucleus and cytoplasm of neurons. Detected in the mitochondrial and microsomal fractions of HEK-293 cells and released into the cytoplasm following cell stress.
蛋白家族：

Peptidase S1 family, Kallikrein subfamily
組織特異性：

In fluids, highest levels found in milk of lactating women followed by cerebrospinal fluid, nipple aspirate fluid and breast cyst fluid. Also found in serum, seminal plasma and some amniotic fluids and breast tumor cytosolic extracts. Not detected in urin
數(shù)據(jù)庫(kù)鏈接：

HGNC: 6367

OMIM: 602652

KEGG: hsa:5653

STRING: 9606.ENSP00000309148

UniGene: Hs.79361

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human